Yang You, Zhong Fangfang, Huang Xiaoming, Zhang Na, Du Jingjing, Long Ze, Zheng Bowen, Lin Wanjun, Liu Wenjun, Ma Wenzhe
State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China; Department of Pediatrics, Affiliated Hospital of Southwest Medical University, Sichuan Clinical Research Center for Birth Defects, Luzhou, Sichuan, China.
State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.
Curr Probl Cancer. 2021 Jun;45(3):100673. doi: 10.1016/j.currproblcancer.2020.100673. Epub 2020 Nov 13.
HOXA5 is considered as an oncogene in many tumors. This study in- vestigated the HOXA5 expression in Chinese acute myeloid leukemia (AML) patients and evaluated the predictive significance of HOXA5 with a single-center retrospective study.
We investigated the expression pattern and prognostic value of HOXA5 in patients with AML through by using a series of databases and various datasets, including the ONCOMINE, TCGA, and STRING datasets. The bone marrow samples of 53 newly diagnosed AML patients (non-M3 subtype) and 19 benign individuals were collected in our center. HOXA5 mRNA expression levels were detected by real-time qPCR, HOXA5 protein expression levels were detected by Western Blot. Clinical data was obtained from inpatient medical records.
Two microarrays in Oncomine showed that the expression level of HOXA5 was significantly upregulated in AML. Our data revealed that AML patients had higher HOXA5 mRNA and protein expression levels than the controls (P < 0.001). The blast percentage in bone marrow of HOXA5 high-expression group was higher that of HOXA5 low-expression group (P < 0.05). Higher expression level of HOXA5 revealed a worse OS in AML (P < 0.05).
Our findings suggested that HOXA5 might have the potential ability to act as a diagnostic biomarker and potential therapeutic target for AML.
HOXA5在许多肿瘤中被认为是一种癌基因。本研究通过单中心回顾性研究，调查了HOXA5在中国急性髓系白血病（AML）患者中的表达情况，并评估了HOXA5的预测意义。
我们通过使用一系列数据库和各种数据集，包括ONCOMINE、TCGA和STRING数据集，研究了HOXA5在AML患者中的表达模式和预后价值。我们中心收集了53例新诊断的AML患者（非M3亚型）和19例良性个体的骨髓样本。通过实时定量PCR检测HOXA5 mRNA表达水平，通过蛋白质免疫印迹法检测HOXA5蛋白表达水平。临床数据来自住院病历。
Oncomine中的两个微阵列显示，HOXA5在AML中的表达水平显著上调。我们的数据显示，AML患者的HOXA5 mRNA和蛋白表达水平高于对照组（P<0.001）。HOXA5高表达组骨髓中的原始细胞百分比高于HOXA5低表达组（P<0.05）。HOXA5的高表达显示AML患者的总生存期较差（P<0.05）。
我们的研究结果表明，HOXA5可能具有作为AML诊断生物标志物和潜在治疗靶点的潜力。
